CYTR News and Press, CytRx Corporation From 03/09/22

CytRx (OTCQB:CYTR) said it is absorbing its subsidiary Centurion BioPharma to bring efficiency and simplicity to its structure. Centurion's assets — which consists of LADR platform being developed for localized delivery of cancer therapeutics — will be taken over by the company ...

Believes Integration Will Bring Enhanced Efficiency and Simplicity to the Company’s Structure Notes the Company Will Fold Centurion into CytRx Dr. Louis Ignarro, Chairman of the Compensation Committee, to Retire from the Board as of the July 2022 Annua...

Notes CytRx's Core Assets Are Unaffected by European Medicines Agency's Assessment of Arimoclomol Highlights Positive Developments Regarding Company's Core Assets, Including Aldoxorubicin CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “C...

Orphazyme Intends to Request a Type C Meeting in Q2 2022 Orphazyme Plans to Resubmit the NDA During H2 2022, Subject to FDA Discussions European Medicines Agency Opinion Expected in Q1 2022 CytRx Corporation (OTCQB: CYTR) (“CytRx” or...

Town Hall to be Led by New CEO Dr. Stephen Snowdy CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories...

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that John Caloz, the Company’s Chief Fina...

Dr. Snowdy to Succeed Steven A. Kriegsman, Who is Stepping Down as CEO and Chairman of the Board CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development in oncology...

Shares of ImmunityBio (IBRX +3.1%), which spiked higher this morning, have pared those gains in late morning trading. Volume as of 1149a is ~4.4M shares, significantly higher than the ~1.3M shares average daily volume. Last week, CytRx Corporation (OTCQB:CYTR -1.0%) highlighted the use o...

Notes Aldoxorubicin is Currently Being Studied in Treatment of Pancreatic Cancer, Triple Negative Breast Cancer and Head and Neck Cancer CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused...

Issues Presentation on Plans, Including Potential Sources of Funding and Benefits to the Las Vegas Community Highlights Centurion BioPharma's Recent Momentum in the Research and Development of Cancer Drugs CytRx Corporation (OTCQB: CYTR) (“CytRx” or the...